SOPHiA GENETICS announced that Karkinos Healthcare will partner with SOPHiA GENETICS and adopt the SOPHiA DDM Platform to advance cancer testing and research for blood cancers and solid tumors to underserved areas in low and middle-income countries. Karkinos Healthcare is a purpose-driven, technology-led oncology platform, focused on early detection, advanced diagnostics, and treatment delivery of common cancers, using its Distributed Cancer Care Network across India. Karkinos Healthcare provides end-to-end solutions for oncology ecosystem, including disease screening, diagnosis, surgery, chemotherapy, radiotherapy and comprehensive patient navigation through the care continuum, in addition to operating advanced research and development laboratories.

The company is on a mission to create 'Community as a Cancer Centre' with an endeavour to serve one million patients annually by addressing the accessibility and affordability gaps in cancer care through a digitally curated hub and spoke and further spoke model, and not restrict cancer care to comprehensive centres alone. In addition, the company will analyse solid tumours for a variety of cancer types including ovarian, prostate, breast, pancreas, lung, colorectal, skin, and brain cancers. The SOPHiA DDM Platform offers tailored NGS-based workflows to streamline processes - from sample to report - to accelerate analysis.

By using the SOPHiA DDM Platform, researchers from Karkinos Healthcare will quickly obtain high-quality and reproducible data that will ultimately accelerate clinical research studies and advance the use of precision medicine.